What Azalea Therapeutics does

Azalea Therapeutics is a preclinical-stage biotechnology company developing in vivo CAR-T cell therapies using its proprietary Envelope Delivery Vehicles (EDV) platform. Founded in 2023 as a spinout from Jennifer Doudna's laboratory at UC Berkeley, the company is engineering a patient's own T cells directly inside the body by delivering CRISPR/Cas9 cargo that integrates CAR constructs at the TRAC locus, eliminating the costly and time-consuming ex vivo manufacturing step required by conventional CAR-T therapies. The lead programs target B cell malignancies (leukemia, multiple myeloma), solid tumors, with the company also signaling expansion into autoimmune diseases and genetic disorders.

The underlying EDV technology functions as a targeted delivery vehicle that selectively locates T cells in vivo and unloads genome engineering payloads with site-specific integration, an approach validated in Nature (March 2026) and at the ASGCT 2026 Annual Meeting where six rhesus macaques exhibited >90% B cell aplasia by Day 10 with no detected neurotoxicity or off-target integration. The company's scientific founders include Nobel laureate Jennifer Doudna (UC Berkeley), Justin Eyquem (UCSF, a leader in TRAC locus CAR engineering), and Michael Fischbach (Stanford bioengineering); Jenny Hamilton serves as co-founder, President, and CEO.

Azalea is pre-revenue with no commercial products, targeting first-in-human trials by the end of 2027. The company plans to monetize through eventual therapeutic product sales, likely via partnerships with larger pharmaceutical companies for development, manufacturing, and commercialization given the platform's breadth across cancer, autoimmune, and genetic indications. It launched in November 2025 with $82 million in seed financing led by Third Rock Ventures and RA Capital Management, with participation from Yosemite and Sozo Ventures.

Name

Azalea Therapeutics

Legal name

Azalea Therapeutics, Inc.

Website

https://azaleatx.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

11–50 employees

Short description

Azalea Therapeutics is a preclinical biotech developing in vivo CAR-T therapies via its proprietary Envelope Delivery Vehicle (EDV) platform, which uses CRISPR-based genome editing to engineer patients' T cells directly inside the body without ex vivo manufacturing.

Ownership category

akta.pro rank

Product category

Cancer Immunotherapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

akta.pro secondary industries

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)

Keywords

• In vivo gene editing
• CAR-T cell therapy
• Genome engineering platform
• Cancer immunotherapy
• Precision genomic medicines

Headquarters

HQ city

Berkeley

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Therapeutic Product Sales: Azalea Therapeutics is developing novel in vivo CAR-T therapies for cancer, autoimmune diseases, and genetic disorders. Once approved, the company would generate revenue through commercial sales of these precision genomic medicines. As a pre-revenue biotech in development stage, the company is currently focused on advancing clinical studies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Azalea Therapeutics is a preclinical biotechnology company developing in vivo CAR-T cell therapies and precision genomic medicines using its proprietary Envelope Delivery Vehicles (EDV) platform. The EDVs act as targeted delivery vehicles that locate T cells in the patient and deliver CRISPR-based genome engineering cargo directly inside the body, eliminating the need for ex vivo cell manufacturing. Programs span cancer (B cell malignancies and solid tumors), autoimmune diseases, and genetic disorders, with first-in-human trials planned by end of 2027.

Product overview

Azalea Therapeutics is developing a unified platform centered on its proprietary EDV (Envelope Delivery Vehicles) technology for in vivo precision genome engineering. The platform enables T cells to be engineered directly inside patients' bodies without ex vivo manufacturing, producing functional CAR T cells that target cancer cells. The company is advancing multiple programs including CAR-T therapies for hematological cancers and autoimmune diseases, with initial clinical focus on B cell aplasia indications. The EDV platform serves as the core enabling technology underpinning all therapeutic programs.

Differentiator

Problem solved

Functional benefit

Products and services

• EDV (Envelope Delivery Vehicles) Platform Proprietary envelope-based delivery technology designed to specifically locate T cells within patients and deliver genome engineering cargo directly inside the body, enabling in vivo CAR-T cell engineering without ex vivo manufacturing. The platform underpins Azalea's therapeutic pipeline across cancer, autoimmune diseases, and genetic disorders.
• In Vivo CAR-T Cell Engineering Program Therapeutic program that engineers a patient's own T cells into functional CAR T cells directly inside the body using the EDV platform and site-specific TRAC-locus integration, eliminating the need for ex vivo cell manipulation. Initial targets include B cell-driven hematologic cancers and solid tumors.
• Precision Genomic Medicines Pipeline Broader therapeutic pipeline of in vivo genomic medicines developed using the EDV platform, targeting the right cells and then the precise genetic locus to create treatments for cancer, autoimmune diseases, and genetic disorders inside the body.

Quantifiable outcome

• Greater than 90% B cell aplasia in peripheral blood by Day 10 in non-human primates
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Three partnerships are on record, tiered core.

• University of California, BerkeleycoreStrategic or Co-development PartnerAzalea Therapeutics is a spinout from Jennifer Doudna's lab at UC Berkeley. Jennifer Doudna serves as co-founder and Nobel Laureate. The company leverages research and intellectual property from the university.
• UCSFcoreStrategic or Co-development PartnerCo-founder Justin Eyquem is Associate Professor of Medicine at UCSF. The dual-vector system for in vivo CAR-T generation was developed by scientists at UCSF and collaborators.
• Stanford UniversitycoreStrategic or Co-development PartnerCo-founder Michael Fischbach is Professor of Bioengineering at Stanford University, contributing scientific expertise to the company's platform development.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Interius BioTherapeutics: Interius is developing in vivo gene delivery using engineered viral vectors to generate CAR-T and other engineered cell therapies directly in the patient. Closely aligned mechanism (in vivo gene delivery for cell therapy) and comparable preclinical/early clinical stage.
• Capstan Therapeutics: Capstan is developing in vivo cell engineering, including in vivo CAR-T, using targeted lipid nanoparticles to deliver mRNA payloads that reprogram immune cells directly inside patients. Closely comparable to Azalea's EDV-based approach on both modality (in vivo cell engineering) and target indications (cancer, autoimmune).
• Umoja Biopharma: Umoja is building an in vivo CAR-T platform using its VivoVec platform with lentiviral particles designed to deliver CAR genes to T cells in situ. Direct in vivo CAR-T competitor targeting hematologic malignancies and solid tumors with overlapping scientific approach.

Broad incumbents

• Allogene Therapeutics: Allogene is a clinical-stage allogeneic (off-the-shelf) CAR-T company with multiple oncology programs in clinic. While pursuing an ex vivo allogeneic rather than in vivo approach, it represents the dominant strategic competitor for next-generation CAR-T in the same indications Azalea targets.
• Beam Therapeutics: Beam is a clinical-stage base editing company with both ex vivo cell therapy and in vivo programs. It is a broad incumbent in the precision gene editing space with significant funding and earlier-stage clinical readouts that compete for the same partnership and BD dollars.
• Editas Medicine: Editas is a clinical-stage CRISPR gene editing company developing both ex vivo cell therapies (including oncology cell therapy programs) and in vivo approaches. Comparable on editing platform and cell therapy focus, though with broader therapeutic ambitions and earlier-stage in vivo pipeline.
• Intellia Therapeutics: Intellia is a clinical-stage in vivo CRISPR/Cas9 gene editing company with LNPs for in vivo delivery. It is a broad incumbent with a more mature in vivo editing platform and significantly larger resources, targeting transthyretin amyloidosis and HAE; in vivo oncology editing remains a strategic adjacency.

Emerging players

• Orna Therapeutics: Orna is developing in vivo gene editing and cell therapy programs using engineered circular RNA and lipid nanoparticle delivery. While initially focused on red blood cell engineering and oncology, its LNP-based in vivo delivery platform competes for the same scientific and commercial whitespace as Azalea.
• Cabaletta Bio: Cabaletta is developing CAR-T therapies with an initial focus on autoimmune diseases (e.g., lupus, myositis), overlapping Azalea's autoimmune indication strategy. Differs in using ex vivo CD19 CAR-T rather than in vivo engineering.
• Caribou Biosciences: Caribou is a clinical-stage CRISPR-based allogeneic CAR-T developer using Cas12a chRDNA genome editing. Comparable on cell therapy modality and genome editing technology, though pursuing ex vivo rather than in vivo manufacturing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/azalea-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Azalea Therapeutics